New Long-Acting shot for schizophrenia enters early human testing
NCT ID NCT06674694
First seen Nov 17, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This early-stage study is testing a single dose of a long-acting injectable form of the drug brexpiprazole in healthy volunteers and people with schizophrenia. The main goal is to see if the injection is safe and tolerable, and how the body processes the drug. The study involves 56 participants and is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA DISORDERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anding Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.